Company profile: Vanqua Bio
1.1 - Company Overview
Company description
- Provider of next-generation medicines for neurodegenerative diseases, including GCase programs to improve lysosomal function for GBA1 Parkinson’s, idiopathic Parkinson’s, and Dementia with Lewy Bodies; a C5aR1 program to reduce complement-mediated inflammation in neurodegenerative and peripheral inflammatory diseases; and VQ-101, a small-molecule GCase activator designed to cross the blood-brain barrier.
Products and services
- VQ-101: BBB-permeable small molecule GCase activator that crosses the blood–brain barrier to treat GBA-Parkinson’s and related disorders by restoring lysosomal function
- GCASE – GBA Parkinson’s Disease: GBA1-targeted program that treats Parkinson’s disease by targeting the GBA1 gene and correcting lysosomal dysfunction
- Complement Pathway – C5aR1: Antagonist-based program reducing complement-mediated inflammation in neurodegenerative and peripheral inflammatory diseases through C5aR1 antagonism
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vanqua Bio
Algynomics
HQ: United States
Website
- Description: Provider of a research-stage pain diagnostics platform leveraging patient cohorts to deliver prospective data that identifies individuals at increased risk for chronic pain, enabling targeted preventive efforts and enhancing patient stratification in clinical trials to identify treatment responders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algynomics company profile →
Oligomerix
HQ: United States
Website
- Description: Provider of target identification and validation technologies to enhance drug discovery for neurodegenerative diseases, and tau-targeting therapeutics including OLX-07010, a Phase 1 small molecule inhibitor of tau self-association, a series of tau small molecule inhibitors, and companion biomarker programs to aid diagnosis and monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oligomerix company profile →
Shape Therapeutics
HQ: United States
Website
- Description: Provider of AI-enabled RNA therapeutics and gene therapy technologies, including the ShapeTX AI Engine for data-driven medicine development; RNA Medicines for discovery and design; RNAfix recruiting ADAR to recode RNA; RNAskip suppressor tRNA addressing premature stop codons; RNAswap smart-sensing vectors for tailored gene expression; and Precise Delivery engineered capsids for targeted RNA delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shape Therapeutics company profile →
Accelerated Care Plus
HQ: United States
Website
- Description: Provider of rehabilitation and dysphagia treatment technologies and services, including OmniVR virtual reality therapy with 3D motion capture; OmniVersa multi-modality electrotherapy and ultrasound for pain management; Synchrony Dysphagia Solutions using surface electromyography and patterned electrical stimulation; ACPlus cloud platform for skilled nursing facilities with EHR integration and analytics; clinical services and ACP University continuing education.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Accelerated Care Plus company profile →
Gabather
HQ: Sweden
Website
- Description: Provider of research and development of innovative therapeutics for neuropsychiatric disorders, focusing on pro-cognitive drug candidates targeting GABAA receptor systems for central nervous system disorders, including GT-002, a small-molecule GABAA receptor PAM in clinical development to improve learning and memory, reduce anxiety, and promote social interaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gabather company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vanqua Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vanqua Bio
2.2 - Growth funds investing in similar companies to Vanqua Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vanqua Bio
4.2 - Public trading comparable groups for Vanqua Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →